These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38089670)

  • 1. Seroconversion and safety of Covid-19 vaccines in pa-tients with chronic liver disease and liver transplant: A systematic review.
    Elzouki AY; Elshafei MN; Aziz A; Elzouki I; Waheed MA; Farooqui K; Azad AM; Habas E; Danjuma MI
    Qatar Med J; 2023; 2023(3):21. PubMed ID: 38089670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis.
    Cheung KS; Mok CH; Mao X; Zhang R; Hung IF; Seto WK; Yuen MF
    Clin Mol Hepatol; 2022 Oct; 28(4):890-911. PubMed ID: 36263669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
    Thuluvath PJ; Robarts P; Chauhan M
    J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
    Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
    BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of COVID-19 vaccines in chronic liver disease patients and liver transplant recipients: A systematic review and meta-analysis.
    Luo D; Chen X; Du J; Mei B; Wang A; Kuang F; Fang C; Gan Y; Peng F; Yang X; Dahmen U; Li B; Song S
    Liver Int; 2023 Jan; 43(1):34-48. PubMed ID: 35986903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing immunogenicity and safety of SARS-CoV-2 vaccine in liver transplantation recipients: a systematic review and meta-analysis.
    Luo X; Lessomo FYN; Yu Z; Xie Y
    Front Immunol; 2023; 14():1145081. PubMed ID: 37731498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 vaccine immune response in patients with plasma cell dyscrasia: a systematic review.
    Faizan U; Nair LG; Bou Zerdan M; Jaberi-Douraki M; Anwer F; Raza S
    Ther Adv Vaccines Immunother; 2023; 11():25151355231190497. PubMed ID: 37645011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroconversion After Coronavirus Disease 2019 Vaccination in Patients Awaiting Liver Transplantation: Fact or Fancy?
    Calleri A; Saracco M; Pittaluga F; Cavallo R; Romagnoli R; Martini S
    Liver Transpl; 2022 Feb; 28(2):180-187. PubMed ID: 34564945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective observational cohort study of covid-19 epidemiology and vaccine seroconversion in South Western Sydney, Australia, during the 2021-2022 pandemic period.
    Potter D; Diep J; Munro C; Lin N; Xu R; Wong J; Porritt R; Maley M; Foo H; Makris A
    BMC Nephrol; 2024 Apr; 25(1):131. PubMed ID: 38609846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation.
    Alqahtani SA; Barry M; Memish Z; Hashim A; Alfares MA; Alghamdi SA; Al-Hamoudi WK; Al-Judaibi B; Alhazzani W; Al-Tawfiq JA; Abaalkhail F
    Saudi J Gastroenterol; 2021; 27(4):201-207. PubMed ID: 34100388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis.
    Verleye A; Wijtvliet V; Abrams S; Hellemans R; Bougrea R; Massart A; Pipeleers L; Wissing KM; Ariën KK; De Winter BY; Van Damme P; Abramowicz D; Ledeganck KJ
    Nephrol Dial Transplant; 2022 Jul; 37(8):1566-1575. PubMed ID: 35544087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
    Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients.
    Arslan M; Wiesner RH; Poterucha JJ; Zein NN
    Transplantation; 2001 Jul; 72(2):272-6. PubMed ID: 11477352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of the efficacy and safety of intradermal versus intramuscular hepatitis B vaccination in end-stage renal disease population unresponsive to primary vaccination series.
    Yousaf F; Gandham S; Galler M; Spinowitz B; Charytan C
    Ren Fail; 2015 Aug; 37(7):1080-8. PubMed ID: 26258528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side Effects Associated With Homologous and Heterologous COVID-19 Vaccines: A Cross-Sectional Study in Saudi Arabia.
    Mohammed RA; Yazbik RS; Baajajah LH; Alharthy SF; Alsalahi H; Mahjaa MA; Barakat MM; Badawy MI; Sultan I
    Cureus; 2023 Jan; 15(1):e34030. PubMed ID: 36814743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.